Literature DB >> 1951633

Peripheral T-cell lymphomas. Immunophenotype, lymphokine production, and immunologic functional characteristics of the lymph-node malignant T cells.

S Raziuddin1, T Malatani, S al-Sedairy, A H al-Saigh.   

Abstract

Immunophenotype and functions of the malignant T cells to secrete various T-cell derived lymphokines and to respond in autologous mixed lymphocyte reaction (AMLR) and allogeneic mixed lymphocyte reaction (MLR) of the six patients with peripheral T-cell lymphomas (PTL) are presented. Three cases showed CD3/TcR alpha beta discordance (1 CD3+/TcR alpha beta-; 2 CD3-/TcR alpha beta+) and one showed absence of both these antigens (CD3-/TcR alpha beta-). In addition, we found that 50% of cases expressed CD25+, CD38+, and CD71+ activation antigens. The CD3/TcR alpha beta discordance and expressions of activation antigen noted in these cases were typical and similar to those reported from elsewhere. These malignant T cells from all cases whether CD25+ or CD25- (resting) expressed elevated interleukin-2 receptors (IL-2R) on stimulation with phytohemagglutinin (PHA) or human recombinant interleukin-2(rIL-2), and secreted elevated IL-2 by PHA, than do T cells from patients with tuberculosis (TB) or normal healthy controls. These malignant T cells also demonstrated elevated AMLR but deficient MLR B cells growth factor (BCGF) (except in one unusual case) secretion was increased, whereas B-cell differentiation factor (BCDF) secretion decreased. These results suggest that malignant T cells from lymph nodes of patients with PTL have uniform multiple immunologic defects in IL-2, BCGF, and BCDF lymphokine secretion and respond in AMLR and MLR, which do not correlate with immunophenotype or histologic types. These functions differentiate them from lymph-node T cells of patients with TB or blood T cells of normal healthy controls.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1951633      PMCID: PMC1886345     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Immunologic characterization of human malignant lymphomas.

Authors:  R J Lukes; R D Collins
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

2.  Antigen presentation: comments on its regulation and mechanism.

Authors:  E R Unanue; D I Beller; C Y Lu; P M Allen
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

3.  Immunologic characterization of a helper T-cell lymphoma.

Authors:  M Gramatzki; M F Dolan; A S Fauci; J A Maples; G D Bonnard; D M Strong
Journal:  Blood       Date:  1982-04       Impact factor: 22.113

Review 4.  The autologous mixed-lymphocyte reaction.

Authors:  M E Weksler; C E Moody; R W Kozak
Journal:  Adv Immunol       Date:  1981       Impact factor: 3.543

5.  Hyperreactivity of activated B cells to B cell growth factor in patients with systemic lupus erythematosus.

Authors:  Y Ueda; T Sakane; T Tsunematsu
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

6.  Human T-cell malignancies: Correlative clinical, histopathologic, immunologic, and cytochemical analysis of 23 cases.

Authors:  D M Knowles; J P Halper
Journal:  Am J Pathol       Date:  1982-02       Impact factor: 4.307

7.  Monoclonal antibody studies in non-Hodgkin's lymphoma.

Authors:  A C Aisenberg; B M Wilkes; N L Harris
Journal:  Blood       Date:  1983-03       Impact factor: 22.113

8.  Characterization and expression of the human alpha beta T cell receptor by using a framework monoclonal antibody.

Authors:  M B Brenner; J McLean; H Scheft; R A Warnke; N Jones; J L Strominger
Journal:  J Immunol       Date:  1987-03-01       Impact factor: 5.422

9.  Peripheral T-cell lymphoma: a clinicopathologic study of nine cases.

Authors:  J U Brisbane; L D Berman; R S Neiman
Journal:  Am J Clin Pathol       Date:  1983-03       Impact factor: 2.493

10.  The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer.

Authors:  L L Lanier; N A Federspiel; J J Ruitenberg; J H Phillips; J P Allison; D Littman; A Weiss
Journal:  J Exp Med       Date:  1987-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.